AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion

Noch jemand hier ?

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-second-quarter-financial-results-0

https://www.globenewswire.com/news-release/2024/05/30/2890849/0/en/AVITA-Medical-Announces-FDA-Approval-of-RECELL-GO.html

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-first-quarter-financial-results

https://www.xm.com/research/markets/allNews/reuters/avita-medicals-asx-shares-drop-to-3month-low-on-revenue-forecast-downgrade-53810377

https://announcements.4dsmemory.com/announcements/6226600

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-fourth-quarter-and-full-year-2023

Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS https://seekingalpha.com/news/4056668-cantor-picks-rcel-as-best-2024-medtech-idea-bullish-on-pacb-axgn-cers ... The investment bank said it chose skin restoration products provider AVITA based on its “top-tier” growth rate of around 64% year-over-year and gross margins of approximately 85%. “We believe RECL should trade at a premium to peers given the company’s superior growth profile and best-in-class gross margins,” Cantor analysts wrote in a recent note. Cantor pointed out that AVITA’s recent guidance excluded revenue for the expected launch of PermeaDerm under the company’s distribution agreement with Stedical Scientific. It added that it was increasing its 2024 commercial revenue estimates for the company to $82.9M, which it believes is still “conservative” as it doesn’t include revenue from the launch. ...

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-announces-exclusive-distribution-agreement

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-announces-preliminary-2023-financial-highlights

AVITA Medical Updates Full Year 2023 Guidance https://finance.yahoo.com/news/avita-medical-updates-full-2023-211500090.html

AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-third-quarter-financial-results-51-revenue

AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe https://finance.yahoo.com/news/avita-medical-announces-distribution-partnership-140000550.html

AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives https://finance.yahoo.com/news/avita-medical-announces-preliminary-third-130000951.html

https://hotcopper.com.au/threads/ann-form-8-k.7611749/ AVITA Medical, Inc. (the "Company") will lodge the following Form 8-K with the United states Securities and Exchange Commission (the "SEC") before the market opens on 2 October 2023, being 2 October 2023 AEDT and date of lodgement on the Australian Securities Exchange. The Form 8-K describes a recent U.S. Food and Drug Administration (the "FDA") letter to the Company that is requesting additional information on its premarket approval supplement application for its latest device, RECELL GO. This places the application file on hold for approximately 4 to 6 months while the Company addresses the FDA's questions.

https://beststocks.com/analysts-express-growing-positive-sentiment-t/